Impact of Neointimal Condition and Platelet Reactivity on Intrastent Thrombus at Long-Term Follow-up After 2nd- and 3rd-Generation Drug-Eluting Stent Implantation　― Insights From a Coronary Angioscopy and Pharmacodynamic Study ―-Reference-Cited by-同舟云学术

Impact of Neointimal Condition and Platelet Reactivity on Intrastent Thrombus at Long-Term Follow-up After 2nd- and 3rd-Generation Drug-Eluting Stent Implantation　― Insights From a Coronary Angioscopy and Pharmacodynamic Study ―

Published:2020-11-25 Issue:12 Volume:84 Page:2244-2252
ISSN:1346-9843
Container-title:Circulation Journal
language:en
Short-container-title:Circ J

Author:

Matsuura Takero¹,Ueno Masafumi¹,Watanabe Heitaro¹,Yasuda Masakazu¹,Takase Toru¹,Nakamura Takashi¹,Yamaji Kenji¹,Iwanaga Yoshitaka¹,Miyazaki Shunichi²,Nakazawa Gaku¹

Affiliation:

1. Division of Cardiology, Department of Internal Medicine, Kindai University Faculty of Medicine

2. Saiseikai-Tondabayashi Hospital

Publisher

Japanese Circulation Society

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://www.jstage.jst.go.jp/article/circj/84/12/84_CJ-20-0796/_pdf

Reference33 articles.

1. 1. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 1030–1039.

2. 2. Waksman R, Barbash IM, Dvir D, Torguson R, Ben-Dor I, Maluenda G, et al. Safety and efficacy of the XIENCE V everolimus-eluting stent compared to first-generation drug-eluting stents in contemporary clinical practice. Am J Cardiol 2012; 109: 1288–1294.

3. 3. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 2007; 369: 667–678.

4. 4. Stone GW, Rizvi A, Sudhir K, Newman W, Applegate RJ, Cannon LA, et al. Randomized comparison of everolimus- and paclitaxel-eluting stents: 2-year follow-up from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) IV trial. J Am Coll Cardiol 2011; 58: 19–25.

5. 5. Tada T, Byrne RA, Simunovic I, King LA, Cassese S, Joner M, et al. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: Results from a registry of 18,334 patients. JACC Cardiovasc Interv 2013; 6: 1267–1274.